Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
刊名:Urologic Oncology: Seminars and Original Investigations
出版年:2017
出版时间:January 2017
年:2017
卷:35
期:1
页码:34.e17-34.e25
全文大小:612 K
卷排序:35
文摘
We estimate that 38% of pathologic response in patients who receive NAC for muscle-invasive bladder cancer can be attributed to TURBT. Patients who progressed from non-muscle invasive cancer were less likely to respond to TURBT. Identifying which patients respond to NAC and which respond to TURBT is needed to improve the effectiveness of both interventions.